[{"id":"292a3dbb-b477-4dfa-9565-daad0a56598c","acronym":"da VINci","url":"https://clinicaltrials.gov/study/NCT03784040","created_at":"2021-01-18T18:42:48.795Z","updated_at":"2025-02-25T14:27:54.363Z","phase":"Phase 1","brief_title":"Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.","source_id_and_acronym":"NCT03784040 - da VINci","lead_sponsor":"National University Hospital, Singapore","biomarkers":" PD-L1","pipe":" | ","alterations":" HLA-A*24","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • OTSGC-A24"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/21/2019","start_date":" 02/21/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2019-04-08"}]